Floatz logo

209 assets in Breast Carcinoma

Therapeutic assets addressing Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Leuporelin
Breast Carcinoma
University of Michigan Rogel Cancer CenterP3B (63)
Vinorelbine Ditartrate
Breast Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP3B (63)
Vismodegib
Breast Carcinoma
OHSU Knight Cancer InstituteP2B (63)
Carvedilol
Breast Carcinoma
Mayo ClinicP3B (62)
Copper Cu 64-Dota-Trastuzumab
Breast Carcinoma
City of Hope Medical CenterP4B (62)
Entinostat
Breast Carcinoma
National Cancer Institute (NCI)P3B (62)
Perflutren Lipid Microsphere Intravenous Suspension
Breast Carcinoma
Kibo NamP2/3B (62)
Cimetidine
Breast Carcinoma
Ohio State University Comprehensive Cancer CenterP2/3B (61)
Diphenhydramine
Breast Carcinoma
Ohio State University Comprehensive Cancer CenterP2/3B (61)
Famotidine
Breast Carcinoma
Ohio State University Comprehensive Cancer CenterP2/3B (61)
Goserelin
Breast Carcinoma
University of Michigan Rogel Cancer CenterP3B (61)
Ribociclib
Breast Carcinoma
Hongmei Zheng, PhDP2B (61)
Abemaciclib
Breast Carcinoma
UNC Lineberger Comprehensive Cancer CenterP2B (60)
Ceralasertib
Breast Carcinoma
National Cancer Institute (NCI)P2B (60)
Decitabine
Breast Carcinoma
Virginia Commonwealth UniversityP2B (60)
Duloxetine
Breast Carcinoma
European Organisation for Research and Treatment of Cancer - EORTCP3B (60)
Fes F-18
Breast Carcinoma
City of Hope Medical CenterP3B (60)
Fludarabine
Breast Carcinoma
Essen BiotechP2B (60)
Fluorizoparib
Breast Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP3B (60)
Fluzoparib
Breast Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP3B (60)
Furosemide
Breast Carcinoma
European Organisation for Research and Treatment of Cancer - EORTCP3B (60)
Hyaluronidase Zzxf
Breast Carcinoma
Dana-Farber Cancer InstituteP2B (60)
Hydroxychloroquine
Breast Carcinoma
M.D. Anderson Cancer CenterP2B (60)
Rivoceranib
Breast Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP3B (60)
T Leuprolide Injectable Emulsion
Breast Carcinoma
Changchun GeneScience Pharmaceutical Co., Ltd.P3B (60)
(Z)-Endoxifen
Breast Carcinoma
National Cancer Institute (NCI)P2B (60)
Ipilimumab
Breast Carcinoma
Emory UniversityP2B (59)
Talazoparib
Breast Carcinoma
National Cancer Institute (NCI)P2B (59)
Trametinib
Breast Carcinoma
OHSU Knight Cancer InstituteP2B (59)
18f-flt
Breast Carcinoma
University of WashingtonP2B (58)
Bicalutamide
Breast Carcinoma
OHSU Knight Cancer InstituteP2B (58)
Capivasertib
Breast Carcinoma
National Cancer Institute (NCI)P2B (58)
Nivolumab
Breast Carcinoma
OHSU Knight Cancer InstituteP2B (58)
Ranitidine
Breast Carcinoma
Ohio State University Comprehensive Cancer CenterP2/3B (58)
Anhydrous Enol-Oxaloacetate
Breast Carcinoma
Jonsson Comprehensive Cancer CenterP2B (57)
Azacitidine
Breast Carcinoma
University of Illinois at ChicagoP2B (57)
Copanlisib
Breast Carcinoma
National Cancer Institute (NCI)P2B (57)
Dabrafenib
Breast Carcinoma
OHSU Knight Cancer InstituteP2B (57)
Dasatinib
Breast Carcinoma
OHSU Knight Cancer InstituteP2B (57)
Fenofibrate
Breast Carcinoma
Tanta UniversityP2B (57)
Giredestrant
Breast Carcinoma
MedSIRP2B (57)
Isosulfan Blue
Breast Carcinoma
Alliance for Clinical Trials in OncologyP3B (57)
Kenacort
Breast Carcinoma
Memorial Sloan Kettering Cancer CenterP2B (57)
Melatonin
Breast Carcinoma
Tanta UniversityP2B (57)
Oleogel-S10
Breast Carcinoma
Memorial Sloan Kettering Cancer CenterP2B (57)
Panitumumab
Breast Carcinoma
M.D. Anderson Cancer CenterP2B (57)
Cobimetinib
Breast Carcinoma
OHSU Knight Cancer InstituteP1/2CCC (55)
Imp-321
Breast Carcinoma
Immutep S.A.S.P2/3CCC (55)
Sirolimus
Breast Carcinoma
Fudan UniversityP1CCC (55)
Taselisib
Breast Carcinoma
National Cancer Institute (NCI)P2CCC (55)
Showing 51 to 100 of 209 assets
PreviousPage 2 of 5Next